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Background: The leading comorbidities and causes of death in patients with chronic obstruc-
tive pulmonary disease (COPD) are lung cancer and cardiovascular disease. The aim of this
study was to establish the incidence of lung cancer, myocardial infarction and heart failure
in patients with COPD in UK primary care.
Methods: The General Practice Research Database (GPRD) was used to identify a cohort of
1927 patients with a first recorded diagnosis of COPD. This cohort was followed for up to 5
years to identify new diagnoses of lung cancer, myocardial infarction and heart failure.
Mortality was also assessed. The relative risk (RR) of each outcome in the COPD cohort was
compared with that in a control cohort with no diagnosis of COPD.
Results: The risk of lung cancer was significantly increased in individuals with a diagnosis of
COPD compared with those with no COPD diagnosis (RR: 3.33; 95% confidence interval [CI]:
2.33e4.75; adjusted for age, sex and smoking status). A diagnosis of COPD was also associated
with a significant increase in the risk of heart failure (age- and sex-adjusted RR: 2.94; 95% CI:
2.46e3.51) and death (age- and sex-adjusted RR: 2.76; 95% CI: 2.45e3.12), but not myocardial
infarction (age- and sex-adjusted RR: 1.18; 95% CI: 0.81e1.71).
Conclusions: Patients with a diagnosis of COPD are at significantly increased risk of lung
cancer, heart failure and death compared with the general population. They do not appear
to be at increased risk of myocardial infarction.
ª 2010 Elsevier Ltd. All rights reserved.1) 531 3404; fax: þ34 (91) 531 2871.
(L.A. Garcı´a Rodrı´guez).
0 Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is a heteroge-
neous, chronic condition characterized by airflow limitation
that is not fully reversible by treatmentwith b2-agonists.
1We
recently reported the incidenceofCOPD inUKprimarycare to
be 2.6 cases per 1000 person-years.2 Mortality from COPD is
increasing worldwide, with the disease estimated to be the
third leading cause of death by 2020.3
COPD is associated with many comorbidities, but the
leading comorbidities and causes of death in patients with
COPD are lung cancer and cardiovascular disease.4e7
Studies in North America have reported cardiovascular
morbidity and mortality to be approximately twice as high
in patients with COPD as in the general population.8,9 The
prognosis for patients with lung cancer also appears to be
worse in those who have COPD than in patients without this
disease.10
The studies that have been carried out in this area to
date have primarily been cross-sectional and therefore
unable to demonstrate directionality. The aim of this study
was to establish the incidence of lung cancer, myocardial
infarction and heart failure in patients with a new diagnosis
of COPD in UK primary care, and to compare the risk of
these outcomes with that in the general population.
Mortality was also analysed.Methods
Data source
The General Practice Research Database (GPRD) contains
informationenteredbyabout1500primarycarepractitionersFigure 1 Study design: Identification of study cohort and case asc
heart failure; MI, myocardial infarction. NOTE: study outcome Z M(PCPs) and covers a population of more than 4 million indi-
viduals.11,12 It is known tobe representativeof theUKgeneral
population. The database includes the complete medical
records of all individuals registered with participating PCPs,
including demographics, diagnoses (recorded using the
Oxford Medical Information System [OXMIS] and Read
codes13,14), prescriptions (generated automatically from the
GPRD using Multilex codes15) and referrals. PCPs record
OXMIS and Read codes that correspond to pathologies that
they diagnose and also those included in hospital discharge
letters. Smoking status is recorded in the GPRD using specific
OXMIS and Read codes for cigarette smoking as well as the
number of cigars smoked. Data on disease incidence from the
GPRD have been validated in several studies,16,17 including
studies of respiratory diseases and COPD.16e22 Mortality data
have also been validated.23 Incident cases are defined as
those patients who had never been diagnosed with the
outcome under investigation before the start of the study
period.
Study design
We identified a source population of individuals aged 40e89
years between 1 January and 31 December 1996 and
included those who had been enrolled with a PCP for at
least 2 years and who had at least 1 year’s computerized
prescription history (Fig. 1).2 The study was approved by
The Scientific and Ethical Advisory Group (SEAG). We
excluded those with a diagnosis of pulmonary fibrosis,
kyphoscoliosis, asthma or COPD before the start date, in
order to avoid possible inclusion of patients with pre-
existing COPD. Patients with a prior diagnosis of cancer
were also excluded. This source population of 808 513
patients was then followed from the start date until theertainment. COPD, chronic obstructive pulmonary disease; HF,
I, HF, lung cancer or mortality.
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detection of suspected COPD using OXMIS and Read codes
for obstructive lung diseases, chronic bronchitis and
emphysema; meeting one of the exclusion criteria (such as
a diagnosis of cancer); reaching 90 years of age; death; or
the end of this first part of the study period (31 December
1996). Following removal of all personal patient identifiers,
the computerized records of all potential cases (n Z 2351)
were reviewed manually in order to identify definite cases
of COPD. Questionnaires were also sent to the patients’
PCPs to confirm the validity of the COPD diagnosis. This
resulted in a final incident COPD cohort of 1927 patients.
Control population
The same eligibility criteria were used to select a control
cohort who had no record of COPD at any time (nZ 16 546)
from the same source population as the cases. The controls
were matched to the cases by age (1 year) and sex to
control for the confounding effect of these variables on the
outcome of interest. An index date in 1996 was randomly
assigned to each individual in the control cohort.
Time-to-event analysis
Four separate analyses were performed to establish
mortality and the incidence of lung cancer, heart failure
and myocardial infarction in both the COPD and control
cohorts. For the lung cancer, heart failure and myocardial
infarction analyses, individuals with a history of the
outcome under investigation or related disorders were
excluded (e.g. patients with a history of coronary heart
disease were excluded from the myocardial infarction
analysis). Individuals aged 70 years or older who made no
visits to their PCP during the follow-up period were also
excluded. Individuals in each cohort were followed until
the occurrence of one of the following: reaching the age
of 90 years, death, end of this part of the study period
(31 December 2001), or identification of a code of the
outcome under investigation. The mean follow-up for
each outcome was 3.2 years in the COPD cohort and 3.7
years in the control cohort.
Statistical analysis
The incidence per 1000 person-years was calculated for
each outcome in the COPD and control cohorts. The relative
risk (RR) of each outcome in the COPD cohort compared
with the control cohort was then calculated and adjusted
by age and sex. In the lung cancer study, the RR was also
adjusted by smoking status. Patients were classified as
current smokers if their last recorded smoking code indi-
cated that the patient smoked at the index date. Former
smokers were those whose last smoking code indicated that
they had stopped smoking prior to the index date. Never
smokers were classified as individuals who had a recorded
code indicating that they had never been a cigarette
smoker or a recorded code indicating zero cigars smoked.
Time-dependent variables such as drug exposure and
comorbidities diagnosed during the follow-up period were
not assessed in these analyses.Caseecontrol analyses were then performed to adjust
the risk of lung cancer, myocardial infarction or heart
failure associated with COPD by possible confounding
variables. Odds ratios (OR) and 95% confidence intervals
(CI) were calculated. In each case, the final regression
model was adjusted for all factors that may have been
clinically relevant to the development of each outcome and
that behaved as potential confounders in the analysis.
Thus, in the lung cancer analysis the OR was adjusted for
sex, age, calendar year, smoking status, the number of PCP
visits, referrals and hospitalizations, as well as the pres-
ence of COPD, ischaemic heart disease and depression. In
the heart failure analysis, the model was adjusted for age,
sex, body mass index (BMI), calendar year, smoking status,
alcohol use, PCP visits, referrals or hospitalizations,
ischaemic heart disease, cerebrovascular disease, hyper-
tension, hyperlipidaemia and diabetes, while in the
myocardial infarction analysis the OR was adjusted for age,
sex, smoking status and PCP visits.
Statistical analysis was performed using StatView
Version 5.0 (SAS Institute) and Stata/IC 10.1.
Results
Lung cancer
After exclusions, the incident COPD cohort for this study
consisted of 1924 individuals and the control cohort con-
sisted of 16 108 individuals. During the follow-up period, 48
individuals in the COPD cohort were considered to have
received a new diagnosis of lung cancer, after a manual
review of their clinical records, compared with 82 in the
control cohort. This represents an incidence of 7.8 per 1000
person-years in the COPD cohort (95% CI: 5.9e10.4) and 1.4
per 1000 person-years in the control cohort (95% CI:
1.1e1.7). After adjusting for age, sex and smoking status,
the RR of a lung cancer diagnosis in the COPD cohort
compared with the control cohort was 3.33 (95% CI:
2.33e4.75). After further adjusting for PCP visits, referrals
and hospitalizations during the follow-up period, the RR
increased to 4.26 (95% CI: 2.92e6.20). This increase in risk
was observed regardless of the number of PCP consultations
(data not shown).
Risk factors for a diagnosis of lung cancer are shown in
Table 1. A significant increase in the risk of a lung cancer
diagnosis was found in individuals who were current or
former smokers, in those with 11 or more PCP visits in the
previous year, and in those who had been referred or
hospitalized in the previous year. A history of ischaemic
heart disease or depression was associated with a signifi-
cant decrease in the risk of a lung cancer diagnosis. There
was no association between BMI or alcohol intake and the
risk of a lung cancer diagnosis.
After adjusting the caseecontrol analysis for sex, age,
calendar year, smoking, PCP visits, referrals and hospitali-
zations, COPD, ischaemic heart disease and depression
(which were the factors that remained associated with
a lung cancer diagnosis in the multivariable model), the risk
of lung cancer among patients with COPD was almost 4
times higher than that in individuals without COPD (OR:
3.95; 95% CI: 2.39e6.52).
Table 1 Prevalence of potential risk factors for lung cancer among patients with a diagnosis of lung cancer and individuals
with no lung cancer diagnosis, and the association between these risk factors and a diagnosis of lung cancer.
Control. (N Z 1000) Lung cancer (N Z 130) ORa (95% CI)
n (%) n (%)
Original cohort
Control cohort 907 (90.7) 82 (63.1) 1 ()
COPD cohort 93 (9.3) 48 (36.9) 3.95 (2.39e6.52)
Age (years)
40e59 55 (5.5) 7 (5.4) NA NA
60e79 703 (70.3) 92 (70.8) NA NA
80e89 242 (24.2) 31 (23.8) NA NA
Sex
Male 723 (72.3) 95 (73.1) NA NA
Female 277 (27.7) 35 (26.9) NA NA
Calendar year
1996 228 (22.8) 32 (24.6) NA NA
1997 277 (27.7) 35 (26.9) NA NA
1998 237 (23.7) 31 (23.8) NA NA
1999 157 (15.7) 19 (14.6) NA NA
2000 78 (7.8) 10 (7.7) NA NA
2001 23 (2.3) 3 (2.3) NA NA
BMI (kg/m2)
19 34 (3.4) 9 (6.9) 0.96 (0.37e2.50)
20e24 273 (27.3) 45 (34.6) 1 ()
25e29 334 (33.4) 40 (30.8) 0.91 (0.54e1.52)
30 109 (10.9) 9 (6.9) 0.39 (0.17e0.90)
Unknown 250 (25.0) 27 (20.8) 0.69 (0.36e1.33)
Smoking status
Never 561 (56.1) 29 (22.3) 1 ()
Current 168 (16.8) 55 (42.3) 5.18 (3.01e8.91)
Former 164 (16.4) 34 (26.2) 3.13 (1.77e5.55)
Unknown 107 (10.7) 12 (9.2) 2.52 (1.18e5.40)
Alcohol use (units per week)
None 338 (33.8) 48 (36.9) 1 ()
1e15 352 (35.2) 42 (32.3) 1.10 (0.66e1.84)
16e42 90 (9.0) 13 (10.0) 1.17 (0.55e2.49)
43 8 (0.8) 2 (1.5) 1.37 (0.24e7.81)
Unknown 212 (21.2) 25 (19.2) 0.97 (0.46e2.03)
PCP visits
0e2 304 (30.4) 14 (10.8) 1 ()
3e10 545 (54.5) 61 (46.9) 1.35 (0.70e2.60)
11 151 (15.1) 55 (42.3) 3.95 (1.93e8.10)
Referral or hospitalization
No 493 (49.3) 22 (16.9) 1 ()
Yes 507 (50.7) 108 (83.1) 3.55 (2.07e6.07)
Ischaemic heart disease
No 781 (78.1) 104 (80.0) 1 ()
Yes 219 (21.9) 26 (20.0) 0.45 (0.26e0.77)
Depression
No 847 (84.7) 114 (87.7) 1 ()
Yes 153 (15.3) 16 (12.3) 0.37 (0.20e0.71)
NA: not applicable due to the matching design. CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio;
PCP, primary care physician; BMI, body mass index.
a Adjusted for sex, age, calendar year, smoking, PCP visits, referral and hospitalizations, COPD, ischaemic heart disease and
depression.
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After exclusions, 1627 individuals from the COPD cohort and
15 238 individuals from the control cohort were eligible to
be included in the heart failure study. After manual review
of the clinical records of patients in the COPD cohort who
had codes related to heart failure, we identified 153 with
new diagnoses of heart failure (incidence: 29.4 cases per
1000 person-years). Thirty-five of these patients (22.9%)
were hospitalized and 13 (8.5%) died within 30 days of
diagnosis. After a manual review of patient profiles with
heart failure codes in the control cohort, we identified 635
individuals who had new diagnoses of heart failure (inci-
dence: 11.5 cases per 1000 person-years). Of these, 152
patients (23.9%) were hospitalized and 66 (10.4%) died
within 30 days of diagnosis.
The age- and sex-adjusted RR of a diagnosis of heart
failure in the COPD cohort was 2.94 (95% CI: 2.46e3.51).
The RR of hospitalization after an episode of heart failure
was 2.81 (95% CI: 1.94e4.07) and the RR of death within 30
days of a heart failure diagnosis was 2.48 (95% CI:
1.36e4.54).
Risk factors for a diagnosis of heart failure are shown in
Table 2. A diagnosis of heart failure was significantly asso-
ciated with age 80e89 years, 3 or more PCP visits in the
previous year, referral or hospitalization, and a history of
ischaemic heart disease, cerebrovascular disease or
hypertension. When adjusted for age, sex, BMI, calendar
year, smoking, alcohol use, PCP visits, referrals or hospi-
talization, ischaemic heart disease, cerebrovascular
disease, hypertension, hyperlipidaemia and diabetes, the
OR of a diagnosis of heart failure in the COPD cohort was
2.54 (95% CI: 2.02e3.19).Myocardial infarction
After exclusions, 1532 individuals with a new diagnosis of
COPD and 13 500 individuals from the control cohort were
eligible to be included in the myocardial infarction study.
After manual review of all patient profiles with a recorded
code of myocardial infarction, 31 incident cases of
myocardial infarction were identified in the COPD cohort
(6.3 cases per 1000 person-years), 10 of which were fatal.
By comparison, there were 269 incident cases in the control
cohort (5.4 cases per 1000 person-years), 81 of which were
fatal.
There was no significant increase in the overall risk of
myocardial infarction in the COPD cohort compared with
the control cohort (age- and sex-adjusted RR: 1.18; 95% CI:
0.81e1.71). There was also no significant increase in the
risk of myocardial infarction when fatal myocardial infarc-
tion (age- and sex-adjusted RR: 1.31; 95% CI: 0.68e2.54)
and non-fatal myocardial infarction (age- and sex-adjusted
RR: 1.12; 95% CI: 0.71e1.75) were studied separately. In
the first year of follow-up, there were 12 deaths due to
myocardial infarction in the COPD cohort (incidence: 8.6
per 1000 person-years; 95% CI: 4.9e15.2) and 78 in the
control cohort (incidence: 5.9 per 1000 person-years; 95%
CI: 4.8e7.4). There was no significant association between
COPD and the risk of death due to myocardial infarction in
the first year of follow-up (RR: 1.45; 95% CI: 0.79e2.66).Risk factors for a diagnosis of myocardial infarction are
shown in Table 3. A diagnosis of myocardial infarction was
significantly associated with current smoking, age 60e89
years, 20 or more PCP visits in the previous year, and
referral or hospitalization. After adjusting by smoking, PCP
visits, referrals and hospitalization as well as age and sex,
the caseecontrol analysis showed that a diagnosis of COPD
was not significantly associated with the risk of a first ever
episode of myocardial infarction (OR: 0.93; 95% CI:
0.62e1.39).
Mortality
During the follow-up period, there were 343 deaths in the
COPD cohort (17.8%; 95% CI: 16.2e19.6) and 1152 in the
control cohort (7.0%; 95% CI: 6.6e7.4). Cumulative survival
during the 5-year follow-up period was significantly higher
among controls than among patients with COPD (Fig. 2).
Individuals with COPD had a significantly higher risk of
death than those with no diagnosis of COPD (age- and sex-
adjusted RR: 2.76; 95% CI: 2.45e3.12). After also adjusting
for smoking, alcohol consumption, BMI and previous
morbidity, the risk of death remained significantly higher
among patients with COPD (RR: 2.25; 95% CI: 1.96e2.58).
The adjusted RR of death among patients with COPD was
higher during the first year of follow-up (RR: 2.68; 95% CI:
2.18e3.30) than the rest of the follow-up period.
Causes of death in the first year of follow-up are shown
in Table 4. Death from a cardiovascular or cerebrovascular
event was more common in the control cohort than in the
COPD cohort (41.8% vs 30.2% of deaths), while death due to
respiratory causes was more common in the COPD cohort
than the control cohort (34.3% vs 13.1% of deaths).
Discussion
This study shows that individuals with a diagnosis of COPD
are at increased risk of lung cancer, heart failure and death
in the first 5 years following their initial COPD diagnosis,
when compared with controls with no diagnosis of COPD.
However, they do not appear to be at increased risk of
myocardial infarction.
A number of potential factors could explain the associ-
ation between COPD, lung cancer and heart failure.
Perhaps the most obvious of these is the shared risk factor
of cigarette smoking. However, we found that a diagnosis of
COPD was associated with an increased risk of a subsequent
diagnosis of lung cancer, heart failure or mortality even
after controlling for smoking status. Moreover, it has
previously been shown that COPD is associated with
increased mortality from lung cancer even in individuals
who have never smoked.24 It seems likely that this increase
in lung cancer and mortality is related to poor lung func-
tion. A meta-analysis of four studies that took account of
smoking status (n Z 204 990) found that individuals in the
lowest quintile of forced expiratory volume in 1 s (FEV1) had
a significantly increased risk of lung cancer compared with
those with higher FEV1 (pooled RR: 2.36; 95% CI:
1.88e3.00).25
Another study considering FEV1 in 1861 healthy individ-
uals found that those in the lowest FEV1 quintile had
Table 2 Prevalence of potential risk factors for heart failure among patients with a diagnosis of heart failure and individuals
with no diagnosis of heart failure, and the association between these risk factors and a diagnosis of heart failure.
Controls (N Z 5000) Heart failure (N Z 788) ORa (95% CI)
n (%) n (%)
Original cohort
Control cohort 4610 (92.2) 635 (80.6) 1 ()
COPD cohort 390 (7.8) 153 (19.4) 2.54 (2.02e3.19)
Age (years)
40e59 296 (5.9) 27 (3.4) 1 ()
60e79 3135 (62.7) 453 (57.5) 1.24 (0.80e1.91)
80e89 1569 (31.4) 308 (39.1) 1.83 (1.17e2.86)
Sex
Male 2886 (57.7) 468 (59.4) 1 ()
Female 2114 (42.3) 320 (40.6) 0.95 (0.80e1.13)
Calendar year
1996 858 (17.2) 138 (17.5) 1 ()
1997 1384 (27.7) 210 (26.6) 0.97 (0.76e1.24)
1998 1171 (23.4) 189 (24.0) 1.07 (0.83e1.37)
1999 813 (16.3) 124 (15.7) 0.97 (0.74e1.28)
2000 655 (13.1) 103 (13.1) 0.98 (0.73e1.32)
2001 119 (2.4) 24 (3.0) 1.11 (0.66e1.84)
BMI (kg/m2)
13e19 218 (4.4) 30 (3.8) 1 ()
20e24 1478 (29.6) 187 (23.7) 1.03 (0.66e1.59)
25e29 1528 (30.6) 255 (32.4) 1.28 (0.83e1.97)
30 506 (10.1) 95 (12.1) 1.38 (0.86e2.20)
Unknown 1270 (25.4) 221 (28.0) 1.56 (0.99e2.45)
Smoking status
Never 2885 (57.7) 398 (50.5) 1 ()
Current 869 (17.4) 147 (18.7) 1.16 (0.92e1.45)
Former 625 (12.5) 150 (19.0) 1.43 (1.14e1.79)
Unknown 621 (12.4) 93 (11.8) 0.87 (0.62e1.22)
Alcohol use (units per week)
None 1904 (38.1) 311 (39.5) 1 ()
1e15 1627 (32.5) 242 (30.7) 0.97 (0.80e1.18)
16e42 324 (6.5) 42 (5.3) 0.86 (0.59e1.24)
43 43 (0.9) 7 (0.9) 1.17 (0.50e2.72)
Unknown 1102 (22.0) 186 (23.6) 1.24 (0.93e1.64)
PCP visits
0e2 1628 (32.6) 94 (11.9) 1 ()
3e10 2671 (53.4) 439 (55.7) 2.18 (1.71e2.78)
11 701 (14.0) 255 (32.4) 3.76 (2.84e4.97)
Referrals or hospitalizations
No 2497 (49.9) 256 (32.5) 1 ()
Yes 2503 (50.1) 532 (67.5) 1.36 (1.14e1.62)
Ischaemic heart disease
No 4067 (81.3) 462 (58.6) 1 ()
Yes 933 (18.7) 326 (41.4) 2.37 (2.00e2.82)
Cerebrovascular disease
No 4382 (87.6) 636 (80.7) 1 ()
Yes 618 (12.4) 152 (19.3) 1.26 (1.02e1.56)
Hypertension
No 3288 (65.8) 438 (55.6) 1 ()
Yes 1712 (34.2) 350 (44.4) 1.28 (1.09e1.52)
Hyperlipidaemia
No 4636 (92.7) 695 (88.2) 1 ()
Yes 364 (7.3) 93 (11.8) 1.28 (0.98e1.68)
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Figure 2 Cumulative survival in individuals with a diagnosis
of chronic obstructive pulmonary disease (COPD) and a control
cohort with no diagnosis of COPD (log-rank test: p < 0.0001).
Table 3 Prevalence of potential risk factors for myocardial infarction among patients with myocardial infarction diagnosis and
individuals with no diagnosis of myocardial infarction, and the association between these risk factors and a diagnosis of
myocardial infarction.
Controls (N Z 5000) Myocardial infarction (N Z 300) ORa 95% CI
n (%) n (%)
Original cohort
Control cohort 446 (8.9) 31 (10.3) 1 ()
COPD cohort 4554 (91.1) 269 (89.7) 0.98 (0.66e1.48)
Age (years)
40e59 574 (11.5) 8 (2.7) 1 ()
60e79 1961 (39.2) 84 (28.0) 2.89 (1.39e6.01)
80e89 2465 (49.3) 208 (69.3) 5.89 (2.88e12.07)
Sex
Male 2370 (47.4) 200 (66.7) 1 ()
Female 2630 (52.6) 100 (33.3) 0.45 (0.35e0.57)
Smoking status
Never 2798 (56.0) 147 (49.0) 1 ()
Current 1076 (21.5) 78 (26.0) 1.49 (1.10e2.00)
Former 577 (11.5) 39 (13.0) 1.11 (0.76e1.61)
Unknown 549 (11.0) 36 (12.0) 1.20 (0.82e1.75)
PCP visits
0e2 1773 (35.5) 93 (31.0) 1 ()
3e10 2614 (52.3) 150 (50.0) 1.05 (0.80e1.37)
11 613 (12.3) 57 (19.0) 1.64 (1.15e2.33)
Referral or hospitalization
No 2638 (52.8) 115 (38.3) 1 ()
Yes 2362 (47.2) 185 (61.7) 1.70 (1.31e2.22)
CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PCP, primary care physician.
a Adjusted by age, sex, smoking, PCP visits.
Table 2 (continued )
Controls (N Z 5000) Heart failure (N Z 788) ORa (95% CI)
n (%) n (%)
Diabetes
No 4647 (92.9) 695 (88.2) 1 ()
Yes 353 (7.1) 93 (11.8) 1.27 (0.98e1.66)
BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PCP, primary care physician.
a Adjusted for age, sex, BMI, calendar year, smoking, alcohol use, PCP visits, referrals or hospitalization, ischaemic heart disease,
cerebrovascular disease, hypertension, hyperlipidaemia and diabetes.
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3.36; 95% CI: 1.54e7.34).26 This increased risk was still
present when the analysis was restricted to non-smokers
(RR: 2.68; 95% CI: 1.17e6.15). A meta-analysis of 12 studies
(nZ 83 880) also found reduced FEV1 to be associated with
an increased risk of cardiovascular death, even when only
those studies that adjusted for smoking were included
(pooled RR: 1.77; 95% CI: 1.56e1.97), and when only data
from non-smokers were included (RR: 1.67; 95% CI:
1.35e2.01).26
The link between reduced FEV1, cardiovascular disease
and mortality could be due to systemic inflammation.
Patients with the lowest FEV1 values have the highest levels
of inflammatory markers such as C-reactive protein and
fibrinogen.26,27 This systemic inflammation can be associ-
ated with atherosclerosis, and may therefore be an
important risk factor for cardiovascular morbidity and
mortality.
Table 4 Causes of death during the first year of follow-up in a cohort of individuals with a diagnosis of chronic obstructive
pulmonary disease (COPD) and in a control cohort with no diagnosis of COPD.
COPD cohort (N Z 1927) Control cohort (N Z 16 546)
n % (95% CI) n % (95% CI)
All causes
Total 169 e 373 e
Cardiovascular/
cerebrovascular
51 30.2 (23.8e37.5) 156 41.8 (36.9e46.9)
Respiratory 58 34.3 (27.6e41.8) 49 13.1 (10.1e16.9)
Cancer 31 18.3 (13.2e24.9) 56 15.0 (11.7e19.0)
Other causes 3 1.8 (0.6e5.1) 22 5.9 (3.9e8.8)
Unknown/unspecified 26 15.4 (10.7e21.6) 90 24.1 (20.1e28.7)
Non-respiratory causes
Total 111 e 324 e
Cardiovascular/
cerebrovascular
51 45.9 (36.9e55.2) 156 48.1 (42.8e53.6)
Aortic diseases 3 5.9 (2.0e15.9) 13 8.3 (4.9e13.7)
Cerebrovascular accident 10 19.6 (11.0e32.5) 38 24.4 (18.3e31.7)
Pulmonary thromboembolism 0 e 4 2.6 (1.0e6.4)
Coronary heart disease 22 43.1 (30.5e56.7) 73 46.8 (39.1e54.6)
Other cardiac disorders 16 31.4 (20.3e45.0) 25 16.0 (11.1e22.6)
Cancer 31 27.9 (20.4e36.9) 56 17.3 (13.6e21.8)
Other causes 3 2.7 (0.9e7.6) 22 6.8 (4.5e10.0)
Unknown/unspecified 26 23.4 (16.5e32.1) 93 28.7 (23.2e32.9)
CI, confidence interval.
1698 L.A. Garcı´a Rodrı´guez et al.In contrast with the results of other database studies,9,20
we found no significant association between a diagnosis of
COPD and a subsequent diagnosis of myocardial infarction.
The reasons for this are unclear, but the difference may in
part be explained by the exclusion of patients with a history
of coronary heart disease from the present study. It is
possible that the risk of myocardial infarction may have
been significantly increased if these patients had been
included. It seems unlikely that this finding is due to
selective mortality in the COPD cohort, in fact our study
shows that cardiovascular mortality was more common in
the control cohort than the COPD cohort.
Major strengths of this study include the large sample
size that was accessed through the GPRD, the population-
based sampling process and the long period of follow-up.
Use of the GPRD also allowed incident cases of COPD to be
separated from prevalent cases. Another strength associ-
ated with use of the GPRD is that it is well-validated and is
known to be representative of primary care for the whole
UK population.16,17 However, a limitation of the study is
that it captures only those patients who receive a diagnosis
of COPD. It is possible that COPD may be underdiagnosed in
primary care,28 and it may be diagnosed preferentially in
those patients who have the most risk factors and who are
at most risk of serious comorbidities. In addition, the like-
lihood of being diagnosed could increase with the increase
in healthcare service use. The regression models were
adjusted for the number of PCP visits to minimize the
impact of this effect.
Further work is necessary to confirm the pathophysio-
logical links between COPD, lung cancer and cardiovascular
disease. It would also be interesting to establish whether
there are any specific factors that increase the risk of lung
cancer, heart failure and death in patients with COPD.This study emphasizes the need for clinicians to be
aware of the links between COPD, lung cancer and
cardiovascular disease.4 It is important to bear in mind that
individuals with COPD may need close monitoring for other
risk factors for cardiovascular disease, and to consider
using spirometry in patients with cardiovascular disease.
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